14/02/2026
Are we treating disease — or building subscription medicine?
With semaglutide becoming generic, pharma competition is intense. The new strategy? “Value add.”
One Pharma Company now offers:
• The drug
• A personalised diet & exercise app
• In-app protein powder sales
• Engagement nudges
• Doctors encouraged ( paid )to keep patients on-platform — long term, possibly for life
Commercially brilliant for the Pharmaceutical Company.
Clinically… uncomfortable for me as a doctor practicing comprehensive Preventive Healthcare.
GLP-1 therapies reduce appetite and in turn improve glycemic markers. That’s progress.
But is obesity the only health risk?
Does weight loss alone restore mitochondrial health, muscle strength, endothelial function, sleep architecture, hormonal balance?
Protein does not build muscle. Progressive overload does.
Building Muscle is important . But that can worsen health in some .
Diet and exercise are not accessories to a drug. They are independent regulators of insulin sensitivity, inflammation, autonomic tone, and metabolic flexibility.
I was trained that diabetes and hypertension are lifelong diagnoses. Manage them. Add drugs. Increase doses.
But I’ve practiced medicine where patients move from diabetic to non-diabetic ranges. From hypertensive to normotensive. By restoring physiology — not subscribing to it.
When the same pharma company manufactures the drug, designs the lifestyle advice, sells supplements, owns behavioral data, and nudges lifetime use — we must ask:
Are we building resilient systems?
Or lighter bodies on subscription?
This is not anti-drug.
It is pro-integration.
I believe we have come to a juncture where
Healthcare must decide:
Pathway management — or whole-person restoration?
www.relivhealthy.com